<DOC>
	<DOCNO>NCT01035879</DOCNO>
	<brief_summary>To define relative efficacy , safety tolerability profile oral daily MBX-2982 three different daily dos vs. placebo sitagliptin 100 mg administer 4 week patient treatment-naive take single anti-diabetic medication ( non-TZD , non-injectable ) .</brief_summary>
	<brief_title>Study Evaluate Efficacy , Safety , Tolerability , Pharmacokinetics MBX-2982 Administered Daily 4 Weeks Monotherapy Patients With Type 2 Diabetes</brief_title>
	<detailed_description>Approximately 100 patient randomize study , 20 three MBX-2982 treatment group , 20 placebo , 20 sitagliptin group . Patients take 3 tablet 1 capsule daily . This sample size provide minimum number expect ensure power least 80 % detect 20 % decrease weight mean glucose level associate extend mixed meal tolerance test ( 2 standardize meal ) relative placebo 4 week daily treatment MBX-2982 , assume drop-out rate 20 % common SD 25 % .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>History type 2 diabetes least 3 month duration Treatmentnaïve ( antidiabetic medication ) treat single antidiabetic agent ( exclude insulin , exenatide GLP1 analog , pioglitazone rosiglitazone ) HbA1c 7.08.5 % ( inclusive ) screen BMI ≥ 26 kg/m2 patient recruit U.S Georgia ≥ 22 kg/m2 patient recruit India Any history type 1 diabetes diabetic ketoacidosis History major upper GI surgery Evidence history clinically significant GI illness include dyspepsia , PUD , nausea , diarrhea , malabsorption , etc . History outpatient insulin use within last 1 year ( insulin use hospitalize acceptable ) Weight loss &gt; 10 pound ( 4.5 kg ) 3 month prior screen visit use weight loss medication ( prescription OTC ) within 30 day screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>